NCT03681275PHASE2Recruiting

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Stanford University

Start Date

9/3/2019

Completion Date

11/30/2026

Summary

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Patients undergoing esophagectomy Exclusion Criteria: * Patients with more than mild pulmonary dysfunction * Patients with any neuromuscular disease that might compromise diaphragm function * Patients with abnormal liver or kidney function * Patients taking any immunosuppressant medication (including prednisone) or antifungal medications * History of tuberculosis * Weight loss of \>5% of body weight over previous 6 months * Pregnancy

Interventions

DRUG

Tofacitinib 10 MG [Xeljanz]

DRUG

Placebo to match Tofacitinib

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Diaphragm Injury

Locations

Stanford University Medical Center

Stanford, California 94305

United States